December 20, 2021 -- Twist Bioscience and Sosei Group have formed a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares.
The collaboration will utilize Sosei Heptares' GPCR target proteins, which have been isolated and stabilized using the company's stabilized receptor platform. Twist will leverage its antibody libraries, including two synthetic GPCR-focused antibody libraries, and apply its bioinformatics approaches.
Sosei Heptares will hold exclusive, full global rights to develop and commercialize any antibody leads identified and directed to the targets of interest. Twist will be eligible for an upfront payment, ongoing R&D costs, and future payments based on the achievement of predefined development milestones, the companies said.
No financial terms of the agreement were disclosed.